Amylyx Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On Nov 06, 2025, AMLX reported earnings of -0.37 USD per share (EPS) for Q3 25, beating the estimate of -0.45 USD, resulting in a 19.37% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -5.89% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 12 analysts forecast an EPS of -0.35 USD, with revenue projected to reach -- USD, implying an decrease of -5.41% EPS, and increase of 0.00% in Revenue from the last quarter.
FAQ
What were Amylyx Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Amylyx Pharmaceuticals, Inc. Common Stock reported EPS of -$0.37, beating estimates by 19.37%, and revenue of $0.00, 0% as expectations.
How did the market react to Amylyx Pharmaceuticals, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -5.89%, changed from $13.24 before the earnings release to $12.46 the day after.
When is Amylyx Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 02, 2026.
What are the forecasts for Amylyx Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on 12
analysts, Amylyx Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.35 and revenue of -- for Q4 2025.